Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs for ILD after allo-HSCT
NCT02543073Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Sep 2014
- Primary completion
- Dec 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mesenchymal stem cells in interstitial lung disease (ILD) and Bronchiolitis Obliterans Syndrome (BOS), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Response rate of ILD at 4 weeks. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
interstitial lung disease (ILD)Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT02543073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543073.